In the present study, we aimed to investigate the diagnostic accuracy and clinical utility of key AD‐related plasma biomarkers, including the Aβ42/40 ratio, p‐tau217, ptau217/Aβ42 ratio, p‐tau181, p‐tau231, NfL, and GFAP, with a focus on comorbid conditions, which are frequently found in a real‐world memory clinic population. This evidence concerns the gene NEFL and Alzheimer disease.